That's an awfully broad question.
I would argue that, especially here in CETA, it's particularly dangerous to be increasing intellectual property rights, especially for brand name pharmaceutical companies, when they haven't even met their past commitment to invest in research and development, and when we see that research and development expenditures in Canada have been declining compared to other countries with far less protection for brand name pharmaceutical companies.
To take a broad question and put it a little more simply, I would say that it's very problematic to include it in the CETA and that, in the end, it's not going to benefit Canadians or increase the access to drugs that we'll have.